Press Release
20 Jan 2026
Spring Sciences Australia Ltd (SSA), a leading producer of pharmaceutical-grade medicinal cannabis, today announced a landmark Sales and Purchase Agreement with Switzerland-based KA Pharmaceuticals SA (KA). The multi-year agreement will see SSA supply KA with premium quality medicinal cannabis, unlocking direct access to the Swiss and broader European markets.
Under the terms of the agreement, SSA will deliver up to 3 tonnes per year of clean, compliant medicinal cannabis flower to KA, with each batch accompanied by full Certificates of Analysis and comprehensive regulatory documentation. The collaboration brings together SSA’s advanced Australian cultivation expertise and KA’s established European pharmaceutical distribution network, creating a seamless bridge between two regions united by a commitment to patient wellbeing and clinical quality.
The partnership also opens avenues for tailored wholesale supply and co-branded product development, combining SSA’s Australian cultivation excellence with KA’s established European patient base. This strategic alignment enables both companies to expand access to high-quality, pharmaceutical-grade cannabis products while strengthening trust and recognition across multiple markets.
The collaboration marks an important milestone in SSA’s growth strategy and broader expansion into global markets.
Dr. Steve Newbery, CEO of Spring Sciences Australia, described the agreement as a transformational milestone for SSA:
“This partnership is a pivotal moment for SSA as we expand our footprint beyond Australia. By joining forces with KA Pharmaceuticals, we are not only delivering our pharmaceutical-grade Clean Flower into Europe but also demonstrating that Australian innovation and quality can compete on the global stage. This deal underscores the strength of our production model and provides a solid foundation of recurring revenue as we scale toward full capacity.”
Based in Lugano, Switzerland, KA Pharmaceuticals is committed to delivering safe, reliable, and effective medicinal cannabis products to patients across Europe.
Roberto Algar, CEO of KA Pharmaceuticals, commented:
“Partnering with SSA allows us to offer European patients a consistent, high-quality supply of medicinal cannabis that meets the most stringent pharmaceutical standards. SSA’s Clean Flower Initiative aligns perfectly with our vision of patient safety, transparency, and uncompromising quality. Together, we will set a new benchmark for the industry.”
The agreement directly supports SSA’s Clean Flower Initiative, a pioneering program focused on delivering pharmaceutical-grade cannabis to the global market. It also provides a strong proof point for SSA’s growth story and market leadership ambitions.
Sheldon Kirkpatrick, CFO of SSA, added:
“This deal provides our investors with clear visibility of export driven revenues and demonstrates our ability to form high-value partnerships with respected international players. It’s another critical step in de-risking our growth trajectory and validating our premium positioning.”
Looking ahead, SSA and KA Pharmaceuticals will continue to deepen their collaboration through the Clean Flower Initiative, championing pharmaceutical-grade cannabis as the global standard for patient care. Together, the two companies aim to redefine industry benchmarks for safety, transparency, and clinical quality within the medicinal cannabis sector. United by a shared belief in science-led cultivation and uncompromising integrity, they remain committed to transforming patient care and showcasing Australia’s leadership in clean cannabis on the global stage.
About SSA
Spring Sciences Australia is a pharmaceutical-grade medicinal cannabis company dedicated to producing the highest quality flower using advanced indoor cultivation technologies. With a focus on compliance, innovation, and patient outcomes, SSA is pioneering the Clean Flower Initiative, positioning Australia as a global leader in premium medicinal cannabis.
About KA Pharmaceuticals
KA Pharmaceuticals, headquartered in Lugano, Switzerland, specializes in the import, distribution, and commercialization of pharmaceutical-grade medicinal cannabis products across Europe. With a strong commitment to regulatory compliance and patient well-being, KA partners with global suppliers to deliver consistent, safe, and effective therapies.
Contact Information
For media inquiries, please contact:
Spring Sciences Australia Ltd
info@springsciences.com.au
KA Pharmaceuticals SA
info@kapharmaceuticals.ch